The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells
Authors
Keywords
-
Journal
Cell Communication and Signaling
Volume 18, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-07-14
DOI
10.1186/s12964-020-00612-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours
- (2019) Han Yao et al. Nature Biomedical Engineering
- Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory
- (2019) Mauro Poggio et al. CELL
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- USP22 Deubiquitinates CD274 to Suppress Anticancer Immunity
- (2019) Xing Huang et al. Cancer Immunology Research
- Macrophage-derived CCL5 facilitates immune escape of colorectal cancer cells via the p65/STAT3-CSN5-PD-L1 pathway
- (2019) Chao Liu et al. CELL DEATH AND DIFFERENTIATION
- Blocking PD-L1 for anti-liver cancer immunity: USP22 represents a critical cotarget
- (2019) Xing Huang et al. Cellular & Molecular Immunology
- Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1
- (2018) Chia-Wei Li et al. CANCER CELL
- Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1
- (2018) Jong-Ho Cha et al. MOLECULAR CELL
- Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
- (2018) Gang Chen et al. NATURE
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
- (2018) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Control of CCND1 ubiquitylation by the catalytic SAGA subunit USP22 is essential for cell cycle progression through G1 in cancer cells
- (2018) Victoria J. Gennaro et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Palmitoylation stabilizes PD-L1 to promote breast tumor growth
- (2018) Yi Yang et al. CELL RESEARCH
- HIP1R targets PD-L1 to lysosomal degradation to alter T cell–mediated cytotoxicity
- (2018) Huanbin Wang et al. Nature Chemical Biology
- PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer
- (2017) Xiaohui Zhang et al. International Journal of Clinical Oncology
- PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma
- (2017) V Atsaves et al. LEUKEMIA
- Small-Molecule Sigma1 Modulator Induces Autophagic Degradation of PD-L1
- (2017) Christina M. Maher et al. MOLECULAR CANCER RESEARCH
- Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
- (2017) Riccardo Mezzadra et al. NATURE
- Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
- (2017) Jinfang Zhang et al. NATURE
- CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
- (2017) Marian L. Burr et al. NATURE
- A regulatory role for the co-chaperone FKBP51s in PD-L1 expression in glioma
- (2017) Paolo D'Arrigo et al. Oncotarget
- PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
- (2017) Zijun Y. Xu-Monette et al. Frontiers in Immunology
- Deubiquitination and Stabilization of PD-L1 by CSN5
- (2016) Seung-Oe Lim et al. CANCER CELL
- Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
- (2016) Corey J Langer et al. LANCET ONCOLOGY
- Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
- (2016) Chia-Wei Li et al. Nature Communications
- CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway
- (2016) Qiuyuan Wen et al. Oncotarget
- Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
- (2015) Padmanee Sharma et al. CELL
- RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
- (2015) S. Loi et al. CLINICAL CANCER RESEARCH
- PDL1 Regulation by p53 via miR-34
- (2015) Maria Angelica Cortez et al. JNCI-Journal of the National Cancer Institute
- PDL1 Regulation by p53 via miR-34
- (2015) Maria Angelica Cortez et al. JNCI-Journal of the National Cancer Institute
- Inducible but Not Constitutive Expression of PD-L1 in Human Melanoma Cells Is Dependent on Activation of NF-κB
- (2015) Kavitha Gowrishankar et al. PLoS One
- Paclitaxel Induced B7-H1 Expression in Cancer Cells via the MAPK Pathway
- (2014) Wenrong Gong et al. JOURNAL OF CHEMOTHERAPY
- PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation
- (2014) Muhammad Zaeem Noman et al. JOURNAL OF EXPERIMENTAL MEDICINE
- USP22 Regulates Oncogenic Signaling Pathways to Drive Lethal Cancer Progression
- (2013) R. S. Schrecengost et al. CANCER RESEARCH
- PTEN Loss Increases PD-L1 Protein Expression and Affects the Correlation between PD-L1 Expression and Clinical Parameters in Colorectal Cancer
- (2013) Minmin Song et al. PLoS One
- The Ubiquitin Code
- (2012) David Komander et al. Annual Review of Biochemistry
- USP22 Antagonizes p53 Transcriptional Activation by Deubiquitinating Sirt1 to Suppress Cell Apoptosis and Is Required for Mouse Embryonic Development
- (2012) Zhenghong Lin et al. MOLECULAR CELL
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- USP22 Is Useful as a Novel Molecular Marker for Predicting Disease Progression and Patient Prognosis of Oral Squamous Cell Carcinoma
- (2012) Songlin Piao et al. PLoS One
- USP22 regulates cell proliferation by deubiquitinating the transcriptional regulator FBP1
- (2011) Boyko S Atanassov et al. EMBO REPORTS
- Elevated expression of USP22 in correlation with poor prognosis in patients with invasive breast cancer
- (2011) Youxue Zhang et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Gcn5 and SAGA Regulate Shelterin Protein Turnover and Telomere Maintenance
- (2009) Boyko S. Atanassov et al. MOLECULAR CELL
- Breaking the chains: structure and function of the deubiquitinases
- (2009) David Komander et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- The Putative Cancer Stem Cell Marker USP22 Is a Subunit of the Human SAGA Complex Required for Activated Transcription and Cell-Cycle Progression
- (2008) Xiao-Yong Zhang et al. MOLECULAR CELL
- Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis
- (2007) Ping Zhang et al. MOLECULAR IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now